Back انترفيرون ألفا Arabic Interferón alfa Spanish Interféron alfa French ଇଣ୍ଟରଫେରନ ଆଲଫା OR Альфа интерферон Tatar Interferon alfa Vietnamese
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Subcutaneous,[1] intramuscular[2] |
| ATC code | |
| Identifiers | |
| DrugBank | |
| ChemSpider |
|
  (what is this?) (verify) | |
Interferon alfa (INN) or HuIFN-alpha-Le, trade name Multiferon, is a pharmaceutical drug composed of natural interferon alpha (IFN-α), obtained from the leukocyte fraction of human blood following induction with Sendai virus. Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography. Although the pharmaceutical product is often simply called "interferon alpha" or "IFN-α" like its endogenous counterpart, the product's International nonproprietary name (INN) is interferon alfa (the spelling of 'alfa' with 'f' reflects INN naming conventions).
Interferon alfa is used in a variety of treatments, including certain forms of leukemia, malignant melanoma, non-Hodgkin's lymphoma,[3] hepatitis B, and hepatitis C.[4][5][6] It is typically administered as an injection under the skin.[1]
- ^ a b "Interferon alfa | Cancer information | Cancer Research UK". www.cancerresearchuk.org. Archived from the original on 18 May 2021. Retrieved 2021-10-17.
- ^ "PRODUCT INFORMATION INTRON A Interferon alfa-2b, recombinant For Injection" (PDF). US Food and Drug Administration. Retrieved 1 April 2024.
- ^ Williams CD, Linch DC (1997). "Interferon alfa-2a". British Journal of Hospital Medicine. 57 (9): 436–9. PMID 9274677.
- ^ Woo MH, Burnakis TG (March 1997). "Interferon alfa in the treatment of chronic viral hepatitis B and C". The Annals of Pharmacotherapy. 31 (3): 330–7. doi:10.1177/106002809703100312. PMID 9066942. S2CID 31113832.
- ^ "Interferon alfa - Drug Information - Chemocare". chemocare.com. Archived from the original on 2023-04-21. Retrieved 2021-10-17.
- ^ "Alpha Interferon", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31643203, retrieved 2021-10-17